Biden wants Medicare, Medicaid to cover pricey weight-loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...
pulmonologyadvisor16m
GLP-1RA Dispensing Trends Indicate Shifting Landscape in Obesity Treatment
GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.
As many as 1 in 5 people won't lose weight with GLP-1 drugs, experts say
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
Medscape2h
Diabetes Drugs Promising for Alcohol Use Disorder
Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...
HealthDay on MSN4d
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...
News Medical1d
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and ...
Medscape3h
GLP-1 RA Drug Class Benefits People With SLE, Lupus Nephritis
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.
CMAJ1d
Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes
In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...
Lexaria Bioscience completes dosing for GLP-1 human pilot study #3
Lexaria Bioscience (LEXX) announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of ...
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Eli Lilly reported total tirzepatide sales that rocketed 272% year over year to $11 billion during the first nine months of ...
News Medical on MSN6d
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options
Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering ...